Compare GSK plc (GSK) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tidewater Inc — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while Tidewater Inc trades at $85.27 (market cap $4.21B). The key difference: GSK plc is far larger — about 21.8× Tidewater Inc's market cap, and GSK plc pays a 3.9% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Tidewater Inc for 26 Days on average.
| GSK | TDW | |
|---|---|---|
Market Cap | $91.88B | $4.21B |
Volume | 7,730,529 | 590,005 |
Sector | Health | Energy |
52-Week High | $61.18 | $100.61 |
52-Week Low | $43.24 | $47.29 |
Typical Hold Time | 93 Days | 26 Days |
Enterprise Value | $111.88B | $4.25B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Tidewater (TDW) trades at $85.19, up 2.15% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though 2026 earnings have missed expectations in two quarters. Recent news includes the completion of the Wilson Sons Ultratug acquisition in August 2026, and institutional interest remains strong with BlackRock's $503.2M investment.
Outlook is cautiously optimistic with a consensus price target of $105.50, but risks include earnings volatility and competitive pressures. The stock offers potential upside from operational improvements and acquisition synergies, yet investors should monitor execution on future earnings and market conditions in the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
